相关实验视频

Updated: May 22, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

发现DC20是一种潜在的非核糖逆转录酶抑制剂,具有优良的药理动力学特性

Jia-Yu Liu¹, Meng-Di Ma², Yi-Ming Li¹

¹Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education; Yunnan Key Laboratory of Cross-Border Infectious Disease Control and Prevention and Novel Drug Development, Yunnan Provincial Center for Research & Development of Natural Products; School of Pharmacy, Yunnan University, Kunming 650500, China.

Bioorganic & medicinal chemistry letters

|May 15, 2025

概括

研究人员开发了新的非核酸逆转录酶抑制剂 (NNRTIs),具有强大的抗病毒活性,可对抗HIV-1. 化合物DC20显示出高疗效,优良的生物可用性和低毒性,这表明未来药物开发的巨大潜力.

科学领域:

药用化学医学化学
病毒学病毒学
药理学药理学是指药理学的学科.

背景情况:

非核类逆转录酶抑制剂 (NNRTIs) 在抗病毒治疗中至关重要.
以前的S-DACOs显示出抗病毒潜力,但具有低于最佳的溶解度和生物可用性.
解决这些局限性是开发有效艾滋病毒治疗的关键.

研究的目的:

合成和评估新型S-DACO化合物作为潜在的HIV-1抑制剂.
识别具有改善抗病毒活性,低细胞毒性和有利的药物动力学特征的化合物.
评估化合物对抗耐药HIV-1菌株的疗效.

主要方法:

25种新型S-DACO化合物的合成和化学表征.
对HIV-1_IIIB (EC₅₀) 和细胞毒性 (CC₅₀) 的抗病毒活性在体外评估.
药物动力学研究,包括口服生物可用性评估和对突变菌株 (V106M,K103N,Y181C) 的活性评估.

主要成果:

大多数合成的化合物显示CLogP低于5和强大的抗病毒活性 (EC₅₀:0.860.004μM).
化合物DC20表现出异常强度 (EC₅₀ = 0.004μM),高选择性指数 (SI = 33,552) 和显著的口服生物利用率 (89.1%).
DC20对关键的NRTI耐药突变菌株保持了有效性.

结论:

新型S-DACOs,特别是DC20,显示出有前途的抗病毒活性和有利的类似药物的特性.
DC20的高强度,低毒性和出色的药理动力学使其成为HIV-1药物开发的强有力的候选者.
对DC20的药物可行性进行进一步的研究对于潜在的临床应用是有必要的.

关键词:

抗艾滋病毒-1活动.生物可用性生物可用性没有NNRTIs的NNRTIs 逆转录酶的使用方法这就是S-DACOs.

更多相关视频

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...